Nasal and buccal compositions for controlling snoring

Details for Australian Patent Application No. 2007266902 (hide)

Owner Omega Pharma Captial NV

Inventors Anton, Jean-Christophe; Marin, Denis; Sonie, Serge

Agent Pizzeys

Pub. Number AU-A-2007266902

PCT Pub. Number WO2007/138224

Priority 0651998 01.06.06 FR; 0701176 19.02.07 FR

Filing date 29 May 2007

Wipo publication date 6 December 2007

International Classifications

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 31/70 (2006.01) - Carbohydrates

A61K 36/896 (1970.01) Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

A61K 47/36 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Polysaccharides

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

Event Publications

8 January 2009 PCT application entered the National Phase

  PCT publication WO2007/138224 Priority application(s): WO2007/138224

27 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007266903-Composition for controlling snoring, in the form of a nasal spray

2007266890-1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors